Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 29 May 2020

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022